LGVN Longeveron Corp Quick Ratio

Longeveron Inc. (LGVN) is developing a biotechnological environment for the therapy of age-related pathologies via the Lomecel-B platform. The visualization of market value on GURU.Markets shows a value of 2.58. The business focuses on combating dementia and congenital heart defects in infants using a cellular approach. Furthermore, operational processes are protected by US law, minimizing any geopolitical threats or sanction risks.

Longeveron Corp (LGVN) Quick Liquidity: for the period 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for longeveron.com (LGVN)

- share price and expert price forecast:

Stock Price Longeveron Corp|LGVN - Consensus Target

- market capitalization data:

Market Capitalization Longeveron Corp|LGVN - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Longeveron|LGVN - Company Book Value|Market Value to Book Value Ratio longeveron.com|LGVN - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

LGVN - Annual Net Income

Fundamental valuation:Longeveron Inc.

To filter out default risks, it is essential for an investor to assess the issuer's ability to meet short-term obligations without liquidating inventories. This quick ratio is calculated as the ratio of cash and accounts receivable to current liabilities, which is critical for Longeveron Inc. (LGVN), as the R&D costs for Lomecel-B require a constant supply of liquid cash to maintain the pace of regenerative medicine.

Analysis of competing companies